These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27764180)

  • 21. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil.
    Giugliani R; Martins AM; So S; Yamamoto T; Yamaoka M; Ikeda T; Tanizawa K; Sonoda H; Schmidt M; Sato Y
    Mol Ther; 2021 Jul; 29(7):2378-2386. PubMed ID: 33781915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan.
    Ueda K; Hokugo J
    Expert Opin Drug Saf; 2020 Jul; 19(7):891-901. PubMed ID: 32342708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole Body and CNS Biodistribution of rhHNS in Cynomolgus Monkeys after Intrathecal Lumbar Administration: Treatment Implications for Patients with MPS IIIA.
    Chung JK; Pan L; Palmieri K; Youssef AS; McCauley TG
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29194406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
    Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
    Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative study of idursulfase beta and idursulfase in vitro and in vivo.
    Kim C; Seo J; Chung Y; Ji HJ; Lee J; Sohn J; Lee B; Jo EC
    J Hum Genet; 2017 Feb; 62(2):167-174. PubMed ID: 27829684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
    Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
    Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (Hunter syndrome).
    Serrano CD; Gomez JF
    J Investig Allergol Clin Immunol; 2011; 21(7):571-2. PubMed ID: 22312944
    [No Abstract]   [Full Text] [Related]  

  • 28. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data.
    Giugliani R; Martins AM; Okuyama T; Eto Y; Sakai N; Nakamura K; Morimoto H; Minami K; Yamamoto T; Yamaoka M; Ikeda T; So S; Tanizawa K; Sonoda H; Schmidt M; Sato Y
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).
    Pano A; Barbier AJ; Bielefeld B; Whiteman DA; Amato DA
    Orphanet J Rare Dis; 2015 Apr; 10():50. PubMed ID: 25902842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hunter syndrome: resolution of extensive typical skin lesions after 9 months of enzyme replacement therapy with idursulfase.
    Marín LL; Gutiérrez-Solana LG; Fernández AT
    Pediatr Dermatol; 2012; 29(3):369-70. PubMed ID: 21995841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report.
    Kim S; Whitley CB; Jarnes Utz JR
    Mol Genet Metab; 2017 Sep; 122(1-2):92-99. PubMed ID: 28610913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
    Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
    Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.
    Żuber Z; Różdżyńska-Świątkowska A; Jurecka A; Tylki-Szymańska A
    PLoS One; 2014; 9(1):e85074. PubMed ID: 24454794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idursulfase for the treatment of mucopolysaccharidosis II.
    Clarke LA
    Expert Opin Pharmacother; 2008 Feb; 9(2):311-7. PubMed ID: 18201153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
    Christianto A; Watanabe H; Nakajima T; Inazu T
    Clin Chim Acta; 2013 Aug; 423():66-8. PubMed ID: 23726270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II.
    Cho SY; Lee J; Ko AR; Kwak MJ; Kim S; Sohn YB; Park SW; Jin DK
    Orphanet J Rare Dis; 2015 Oct; 10():141. PubMed ID: 26520066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS).
    Muenzer J; Botha J; Harmatz P; Giugliani R; Kampmann C; Burton BK
    Orphanet J Rare Dis; 2021 Oct; 16(1):456. PubMed ID: 34717704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome.
    Muenzer J; Beck M; Eng CM; Giugliani R; Harmatz P; Martin R; Ramaswami U; Vellodi A; Wraith JE; Cleary M; Gucsavas-Calikoglu M; Puga AC; Shinawi M; Ulbrich B; Vijayaraghavan S; Wendt S; Conway AM; Rossi A; Whiteman DA; Kimura A
    Genet Med; 2011 Feb; 13(2):95-101. PubMed ID: 21150784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.